Shareholder Alert: The Ademi Firm investigates whether Cidara Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

Group 1 - Cidara is involved in a tender offer transaction with Merck, where shareholders will receive $221.50 per share, totaling approximately $9.2 billion [2] - The transaction agreement includes provisions that significantly limit competing offers for Cidara, imposing penalties if a competing bid is accepted [3] - The Ademi Firm is investigating potential breaches of fiduciary duty by Cidara's board of directors regarding their responsibilities to shareholders [3]